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Randomized, Controlled Trial of Ibuprofen Syrup Administered During
Febrile Illnesses to Prevent Febrile Seizure Recurrences
Margriet van Stuijvenberg, MD*‡; Gerarda Derksen-Lubsen, MD, PhD§; Ewout W. Steyerberg, PhD‡;
J. Dik F Habbema, PhD‡; and Henrie¨tte A. Moll, MD, PhD*
ABSTRACT. Objectives. Febrile seizures recur fre-
quently. Factors increasing the risk of febrile seizure
recurrence include young age at onset, family history of
febrile seizures, previous recurrent febrile seizures, time
lapse since previous seizure <6 months, relative low
temperature at the initial seizure, multiple type initial
seizure, and frequent febrile illnesses. Prevention of sei-
zure recurrences serves two useful purposes: meeting
parental fear of recurrent febrile seizures in general and
reducing the (small) risk of a long-lasting and eventually
injurious recurrent seizure. In daily practice, children
with febrile seizures often are treated with antipyretics
during fever to prevent febrile seizure recurrences. Thus
far, no randomized placebo-controlled trial has been per-
formed to assess the efficacy of intermittent antipyretic
treatment in the prevention of seizure recurrence.
Methods. We performed a randomized, double-
blind, placebo-controlled trial. Children 1 to 4 years of
age who had had at least one risk factor for febrile
seizure recurrence were enrolled. They were randomly
assigned to either ibuprofen syrup, 20 mg/mL, 0.25 mL
(5 5 mg) per kilogram of body weight per dose, or
matching placebo, to be administered every 6 hours
during fever (temperature, >38.5°C). Parents were in-
structed to take the child’s rectal temperature immedi-
ately when the child seemed ill or feverish and to
promptly administer the study medication when the
temperature was >38.5°C. Doses were to be adminis-
tered every 6 hours until the child was afebrile for 24
hours. The parents were instructed not to administer
any other antipyretic drug to the child. For measuring
rectal temperature, a Philips HP5316 digital thermom-
eter (Philips, Eindhoven, The Netherlands) was dis-
tributed. During subsequent treatment of the fever
episode, parents had to call the investigator at least
once each day to notify the investigator in case of
febrile seizure recurrence. The investigator could be
contacted by parents 24 hours per day.
The primary outcome was the first recurrence of a
febrile seizure. Kaplan–Meier curves and Cox regres-
sion were used for the statistical analysis. The treat-
ment effect on the course of the temperature was as-
sessed using analysis of covariance, with temperature
at fever onset as covariate. Two analyses were per-
formed. In an intention-to-treat analysis, all first recur-
rences were considered regardless of study medication
compliance. A per-protocol analysis was limited to
those recurrences that occurred in the context of study
medication compliance.
Results. Between October 1, 1994, and April 1, 1996,
230 children were randomly assigned to ibuprofen syrup
(111 children) or placebo (119 children). Median fol-
low-up time was 1.04 years (25th–75th percentiles; 0.7–1.8
years) in the ibuprofen group and 0.98 years (0.7–1.6
years) in the placebo group. Of all children, 67 had a first
febrile seizure recurrence, with 31 in the ibuprofen group
and 36 in the placebo group. The 2-year recurrence prob-
abilities were 32% and 39%, respectively. The recurrence
risk in the ibuprofen group was 0.9 (95% confidence
interval: 0.6–1.5) times the recurrence risk in the placebo
group (intention to treat). Adjustment for baseline char-
acteristics did not affect the risk-reduction estimate. Of
the 67 recurrences, 30 occurred in the context of study
medication compliance (13 ibuprofen, 17 placebo). The
per-protocol analysis, which was limited to these events,
showed similar results.
A significant reduction in temperature (0.7°C) after
fever onset in the ibuprofen group compared with the
placebo group was demonstrated if all 555 fever episodes
were considered. In the fever episodes with a seizure
recurrence, a similar temperature increase was shown in
both groups, with no significant difference between the
intention-to-treat and the per-protocol analysis.
Discussion. The present study failed to demonstrate a
preventive effect of intermittent antipyretic treatment
during fever on the number of febrile seizure recurrences
in children at increased risk. The possibility that antipy-
retics can reduce recurrence has been addressed before.
None of these studies were placebo-controlled trials with
a standardized antipyretic treatment schedule; hence, the
results were inconclusive.
Although it had been described previously that ibu-
profen reduces fever safely and adequately in children
with febrile seizures, which is confirmed by the present
study, we found that fever was not reduced in those fever
episodes in which a recurrence occurred. Factors that may
have influenced these results are discussed.
Preventive treatment alternatives include primarily in-
termittent treatment with diazepam. Only children with
a high recurrence risk may benefit from it. In a meta-
analysis, its efficacy could not be demonstrated. The
most important issue in treating children with febrile
seizures is reducing parental anxiety by providing infor-
mation about the excellent prognosis.
Conclusion. We found no evidence that ibuprofen ad-
ministration during fever prevents febrile seizure recur-
rence. Pediatrics 1998;102(5). URL: http://www.pediatrics.
org/cgi/content/full/102/5/e51; child, febrile convulsions,
recurrence, risk factors, ibuprofen, fever, comparative
study, double blind method, survival analysis, propor-
tional hazards model.
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Febrile seizures are the most common type ofseizures in childhood, with a cumulative inci-dence of 4%1 and an average recurrence risk of
30% in 2 years. Factors increasing the risk of febrile
seizure recurrences include young age at onset, fam-
ily history of febrile seizures, previous recurrent fe-
brile seizures, time lapse since previous seizure ,6
months, temperature ,40.0°C at initial febrile sei-
zure, multiple type initial febrile seizure, and fre-
quent febrile illnesses.2–8
In recent years, the prevention of recurrent febrile
seizures has become a debatable issue; prevention
may not be necessary because almost all febrile sei-
zures are not injurious to the child.9–11 However,
prevention of seizure recurrences serves two useful
purposes: meeting parental fear of recurrent febrile
seizures in general12,13 and reducing the small risk of
a long-lasting and eventually injurious recurrent sei-
zure.9–11
Intermittent treatment with diazepam during fe-
ver is associated with adverse effects and has not
been proven efficacious to prevent febrile seizure
recurrences.14 Intermittent treatment with antipyretic
drugs is likely to be a rational alternative. Although
children with febrile seizures often are treated with
antipyretics in daily practice, until now, no proper
evaluation of the efficacy of antipyretic treatment in
comparison with placebo to prevent febrile seizure
recurrences has been performed.15–17 The aim of this
study is to assess the efficacy of ibuprofen to prevent
febrile seizure recurrence in children at increased
risk for recurrence.
PATIENTS AND METHODS
Patients
Children who were seen for febrile seizure at the Sophia Chil-
dren’s Hospital in Rotterdam and the Juliana Children’s Hospital
in The Hague, The Netherlands, between April 1, 1994, and April
1, 1996, were considered for inclusion in the study. These hospitals
have pediatric emergency wards that are open 24 hours a day.
A febrile seizure was defined according to the National Insti-
tutes of Health consensus as “an event in infancy or childhood,
associated with fever but without evidence of intracranial infec-
tion or defined cause.”18 Criteria for inclusion were febrile seizure
within the past 6 months, age between 1 and 4 years, and presence
of one or more risk factors for febrile seizure recurrence. Risk
factors were defined as a positive first-degree family history of
febrile seizures; an initial febrile seizure of the multiple type; a
temperature ,40.0°C at the initial febrile seizure; and previous
febrile seizure recurrence(s). All parents had to give written in-
formed consent for their child’s participation in the study. Criteria
for exclusion were previous seizures without fever; known allergy
for ibuprofen; current use of antiepileptic drugs; no telephone
connection; non-Dutch- and non-English-speaking parents.
The study protocol was approved by the ethical review boards
of both institutions.
Study Medication
Study medication consisted of either ibuprofen syrup, 20 mg/
mL, 0.25 mL (5 5 mg) per kilogram of body weight per dose, or
matching placebo, to be administered by the parents during fever.
Parents were instructed to take the the child’s rectal temperature
immediately when the child seemed ill or feverish and to admin-
ister study medication promptly when the temperature was
$38.5°C. Each dose was to be administered every 6 hours until the
child was afebrile for 24 hours. Parents were instructed not to
administer any other antipyretic drug to their child.
According to a computer-generated randomization schedule,
which was stratified by center, each child was assigned at study
entry to either the ibuprofen or the placebo arm of the study. Only
the biostatistician and the hospital pharmacists knew the actual
treatment allocation.
Procedures
Baseline characteristics, including demographic characteristics,
characteristics of the initial seizure, and previous seizure recur-
rences, were recorded at study entry. Parents were instructed to
record the precise timing of study medication administration and
the degree of the temperature on a standardized patient form. For
measuring rectal temperature, a Philips HP5316 digital thermom-
eter (Philips, Eindhoven, The Netherlands) was distributed. On
the first day of fever onset, the child visited the outpatient clinic
for assessment of the clinical condition, rectal temperature, com-
pliance to the study protocol, and registration of concomitant
therapy. No laboratory tests were performed unless indicated by
the child’s clinical condition. Antibiotic treatment was prescribed,
if necessary. During subsequent treatment of the fever episode,
parents had to call the investigator at least once each day to notify
the investigator in case of febrile seizure recurrence. The investi-
gator could be contacted by the parents 24 hours per day. If no
fever had been reported after 3 months, the investigator contacted
the parents to verify participation and to check the occurrence of
fever or febrile seizure recurrence. Also, parents were instructed
every 3 months about the dose of study medication to be used to
account for body weight gain.
Statistical Analysis
The outcome was the first recurrent febrile seizure. Follow-up
time at risk for this event was considered ended at the planned
date of study termination (ie, October 1, 1996) or when any seizure
(ie, febrile or nonfebrile) had occurred, the patient had left the
outpatient clinic follow-up, additional participation was refused,
or any medical condition occurred that precluded use of study
medication to treat a fever episode. The cumulative probability
over time at risk of a first febrile seizure recurrence was estimated
using the Kaplan–Meier method.19 The two study medication
groups were compared using Cox proportional hazards analysis,20
with study medication allocation as the only covariate. Risk re-
duction by ibuprofen relative to placebo with its 95% confidence
interval (CI) was estimated from the Cox model. Next, Cox pro-
portional hazards modeling was used to assess whether correction
for differences in baseline characteristics between the two study
medication groups influenced the result.
Two analyses were performed. In an intention-to-treat analysis,
all first recurrent febrile seizures over the follow-up time at risk
defined earlier were considered, regardless of study medication
compliance by the child’s parents. A per-protocol analysis was
limited to those febrile seizure recurrences that occurred in the
context of study medication compliance, defined as administra-
tion of study medication during an episode of fever according to
the protocol before any febrile seizure recurrence had occurred.
The definition of follow-up time at risk was the same in both
analyses.
The treatment effect on the temperature at 6 (62) hours from
fever onset was assessed using analysis of covariance, with tem-
perature at fever onset as covariate.21 Analysis of covariance also
was used to assess the difference between temperature at seizure
recurrence and temperature at fever onset and to assess the treat-
ment effect on the temperature at seizure recurrence. Calculations
were performed using SPSS for Windows, version 6.0.22
Power Calculation
The 2-year probability of seizure recurrence was assumed to be
40% in the placebo group. This relatively high figure was assumed
because of the inclusion criterion of having at least one risk factor
for febrile seizure recurrence. The required power was set at 80%
(b 5 0.20) to detect a halving of the recurrence risk by ibuprofen
(hazard ratio, 0.5) with a type I error (a) of 0.05. Using the Egret
Size package, the required sample size was found to be 220 (110 in
each study medication group).23
RESULTS
Study Population and Protocol Compliance
In total, 478 children were considered for inclu-
sion. Between October 1, 1994, and April 1, 1996, 230
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of these were randomized (Fig 1), 111 to the ibupro-
fen group and 119 to the placebo group to treat any
fever episode that might occur. Baseline characteris-
tics are given in Table 1. The median follow-up time
was 1.04 years (25th–75th percentiles; 0.7–1.8 years)
for ibuprofen and 0.98 years (0.7–1.6 years) for pla-
cebo.
Reasons for termination of follow-up are shown in
Fig 2; 67 children had a first febrile seizure recur-
rence.
During follow-up, 555 fever episodes were re-
ported in 194 children distributed as follows in the
treatment groups: 94 children allocated to ibuprofen
(85% of 111) had a total of 271 fever episodes; 100
children allocated to placebo (84% of 119) had a total
of 284 fever episodes. Table 2 shows that in 377 (68%)
of all 555 fever episodes, study medication was ad-
ministered according to the protocol. Also, the re-
ported use of concomitant medication is given.
In 67 children (ibuprofen group, 31; placebo
group, 36) (Fig 2), a first recurrent febrile seizure
occurred during a fever episode. In the intention-to-
treat analysis, these 67 children were considered as
having reached the outcome studied. Of these, 30
first febrile seizure recurrences occurred in the con-
text of study medication compliance (13 ibuprofen,
17 placebo). The per-protocol analysis was limited to
these events.
Effect of Ibuprofen on Febrile Seizure Recurrence
The cumulative probability over time of a first
febrile seizure recurrence by treatment group as es-
timated by the Kaplan–Meier method based on in-
tention-to-treat (ie, ibuprofen, 31 events; placebo, 36
events) is shown in Fig 3. The 2-year estimated re-
currence probability was 32% for ibuprofen and 39%
for placebo (P 5 .70). The recurrence risk in the
ibuprofen group was 0.9 times the recurrence risk in
the placebo group (CI: 0.6–1.5). The risk reduction
estimate was similar when the analysis was adjusted
for baseline characteristics. A per-protocol analysis
(ie, using the 13 events on ibuprofen and 17 on
placebo for which study medication was used)
showed similar results (risk reduction, 0.8; CI:
0.4–1.7).
Temperature
Table 3 shows that the median temperature at
fever onset was similar in both treatment groups. A
significant reduction of the temperature at 6 (62)
hours after fever onset in the ibuprofen group com-
pared with the placebo group was demonstrated, if
all 555 fever episodes were considered (0.7°C, P ,
.001). In the fever episodes with a first febrile seizure
recurrence, a temperature increase from fever onset
until seizure recurrence was shown (P , .001); the
increase was not significantly different in the ibupro-
fen group compared with the placebo group in nei-
ther the intention-to-treat analysis nor the per-proto-
col analysis (in both analyses, P . .20).
DISCUSSION
The present study failed to demonstrate a preven-
tive effect of intermittent antipyretic treatment with
ibuprofen during fever on the number of febrile sei-
zure recurrences in children with an increased recur-
rence risk. The possibility of antipyretic treatment to
reduce the risk of febrile seizure recurrence has been
addressed before.15–17 Table 4 summarizes the char-
acteristics of these studies. None were placebo-con-
trolled trials with a standardized antipyretic treat-
ment schedule; hence, it is difficult to draw
conclusions from these studies with respect to the
efficacy of antipyretic treatment to prevent febrile
seizure recurrence. Because the present study is the
first placebo-controlled trial of antipyretics to pre-
vent febrile seizure recurrences, one cannot com-
pletely be convinced that ibuprofen does not make a
difference. The results, however, indicate that it is
unlikely that intermittent antipyretic treatment re-
duces the number of febrile seizure recurrences.
We considered ibuprofen to be a promising drug
to reduce the risk of febrile seizure recurrence. Both
ibuprofen and acetaminophen administered orally
have shown to be safe and effective antipyretic drugs
in children with fever.24–26 Because in these studies,
children with febrile seizures were excluded, we as-
sessed the antipyretic efficacy of ibuprofen syrup, 5
mg/kg per 6-hourly dose, versus acetaminophen
syrup, 10 mg/kg per 6-hourly dose, during fever in
children with febrile seizures in a previous study.27
The results indicated that antipyretics administered
orally reduce fever in children with febrile seizures
safely. In the first hours after the initial dose, ibupro-
fen showed a stronger temperature-reducing effect
compared with acetaminophen. We used a similar
6-hourly dose of ibuprofen of 5 mg/kg in the present
study.
We confirmed the temperature-reducing effect ofFig 1. Recruitment of the study participants.
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ibuprofen at 6 hours after administration of the first
dose, when the second dose was to be administered.
The temperature-lowering effect of ibuprofen could
not be demonstrated in those fever episodes in which
a recurrent febrile seizure occurred, in neither the
intention-to-treat analysis nor the per-protocol anal-
ysis (Table 3). Some factors might have played a role
in the reported inability of ibuprofen to reduce fever
in those fever episodes.
The timing of temperature measurement was un-
favorable to demonstrate the maximum antipyretic
efficacy of ibuprofen; if the temperature had been
measured earlier, we might have found a stronger
antipyretic effect.27 However, for the convenience of
the study participants and their parents, the temper-
ature measurements were not taken more frequently
than every 6 hours when the next dose of the study
medication was administered. In addition, the par-
ents may have taken the temperature under some
stress because of their fear of a recurrent seizure,
resulting in a less than optimal reliability of the
measurements. Because this has probably occurred
equally in the ibuprofen and the placebo groups, it is
unlikely that the reported inability of ibuprofen to
reduce fever in those fever episodes with a recur-
rence is attributable to unreliable measurements.
While discussing factors influencing both the in-
ability of the present study to show fever reduction
TABLE 1. Baseline Characteristics by Treatment Group
Ibuprofen
n 5 111 (100%)
Placebo
n 5 119 (100%)
Demographic characteristics
Female gender 41 (37%) 49 (41%)
Age at study entrya 1.9 (1.4–2.4) 1.9 (1.4–2.7)
First-degree family history of febrile seizures* 27 (24%) 32 (27%)
Family history of any seizures 44 (40%) 49 (41%)
Day-care attendance 39 (35%) 49 (41%)
First born 70 (63%) 59 (50%)
Caucasian origin 67 (60%) 78 (66%)
Immunization completedb 85 (77%) 88 (74%)
Initial seizure characteristics
Age at onseta 1.4 (1.1–1.9) 1.5 (1.0–2.1)
FSEc 8 (7%) 12 (10%)
Focal typed 16 (14%) 10 (8%)
Multiple typee* 47 (42%) 40 (34%)
Rectal temperature below 40.0°C* 55 (50%) 66 (56%)
Previous recurrent febrile seizures
Previous recurrent febrile seizures* 39 (35%) 45 (38%)
Time lapse between last seizure and study entrya 0.10 (0.05–0.21) 0.07 (0.04–0.18)
Number of risk factors
1 66 (60%) 66 (56%)
2 33 (30%) 44 (37%)
$3 12 (11%) 9 (8%)
a In years, median (25th–75th percentiles).
b According to the national guidelines for immunization in the Netherlands.
c Febrile status epilepticus, seizure duration $30 min.
d Focal onset of the seizure or postictal Todd’s paresis.
e Seizure recurrence within 24 hours.
* Risk factor for febrile seizure recurrence discussed in “Patients”.
Fig 2. Events terminating follow-up
time at risk (see “Methods,” Statistical
Analysis).
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and prevention of seizure recurrences by ibuprofen,
parents’ noncompliance to the study protocol and
unreported additional use of antipyretics also should
be addressed. Compliance was ensured by using a
standardized patient form on which administration
of the study medication had to be written down by
the parents. We used no marker of medication nor
performed measurement of ibuprofen and acetamin-
ophen blood levels to assess the compliance. The
analysis of the temperature measurements in the
total study group showed a clinically relevant and
statistically significant temperature reduction in the
ibuprofen group. Therefore, substantial compliance
failures and unreported use of antipyretics are rather
unlikely the cause of the inability of our study to
show temperature reduction in those fever episodes
in which a recurrence occurred and also are unlikely
the cause of the inability of the study to show pre-
ventive efficacy on seizure recurrences.
If adequate reduction of fever prevents seizure
recurrences, prevention may be possible only with
the use of a much stronger temperature-reducing
TABLE 2. Compliance and Concomitant Medication Per Fever Episode by Treatment Group
Ibuprofen
n 5 271 (100%)
Placebo
n 5 284 (100%)
Fever episodes without febrile seizure recurrence
Fully compliant 164 (61%) 183 (64%)
Not fully compliant
Parents did not give the study medication and did not report fever promptly 17 (6%) 6 (2%)
Parents deviated from the prescribed dose: 54 (20%) 56 (20%)
and gave additional acetaminophen 4 (1%) 3 (1%)
and gave diazepam rectal solutiona 1 (,1%) –
Fever episodes with febrile seizure recurrence
Fully compliant 13 (5%) 17 (6%)
Not fully compliant
Parents did not give the study medication, because fever was not recognized
before the seizure occurred
11 (4%) 11 (4%)
Parents did not give the study medication for other reasons 7 (3%) 8 (3%)
* Administered of the parents’ own accord to prevent febrile seizure recurrence.
Note: Antibiotic treatment for suspected bacterial infection of the respiratory tract was prescribed for 8 children (1 in the ibuprofen group
and 7 in the placebo group). Two children received continuous antibiotic prophylaxis because of preexisting vesicoureteral reflux (1 in
the ibuprofen group vs 1 in the placebo group).
Fig 3. Cumulative probability over
time of a first febrile seizure recurrence
by treatment group (intention to treat).
TABLE 3. Temperature by Treatment Group
Ibuprofen Group Placebo Group
All fever episodes 271 284
At fever onset 39.1 (38.7–39.4) 39.0 (38.7–39.3)
At 6 (62) hours after fever onset 38.2 (37.3–39.0) 38.9 (38.2–39.3)
Fever episodes with recurrence
Intention-to-treat analysis 31 36
At fever onset 39.0 (38.7–39.7) 39.4 (38.8–39.7)
At febrile seizure recurrence 39.9 (39.0–40.3) 39.6 (39.1–40.0)
Per-protocol analysis 13 17
At fever onset 39.0 (38.6–39.1) 39.5 (38.7–39.8)
At febrile seizure recurrence 40.1 (39.9–40.4) 40.0 (39.4–40.3)
Note: Median temperatures, Celsius (25th–75th percentiles).
http://www.pediatrics.org/cgi/content/full/102/5/e51 5 of 7
 at Erasmus Rotterdam on December 11, 2006 www.pediatrics.orgDownloaded from 
agent, such as a higher dose of ibuprofen, or other
temperature-reducing methods. For example, a dose
of 10 mg of ibuprofen per kilogram might be admin-
istered, which is twice the dose we have used, and
which has been recommended in children with high
fever. It is unknown, however, whether stronger
fever-reducing methods are able to lower the tem-
perature in children with febrile seizures sufficiently
to prevent febrile seizure recurrences.
In addition, specific conditions may affect the
child’s susceptibility to febrile seizure recurrence,
such as conditions determined by the underlying
cause of the feverish illness. The underlying cause of
the fever either may be responsible for antipyretic
treatment to fail in lowering the body temperature
and therefore being ineffective to prevent seizure
recurrences or may provoke a febrile seizure, regard-
less of resistance to any fever-reducing treatment.
In the present study, the per-protocol and the in-
tention-to-treat analyses showed similar results.
Thus, a strong preventive efficacy of ibuprofen is
unlikely, even when it has been administered in
compliance with the study protocol. Nevertheless, it
should be made clear that even if ibuprofen had been
effective, then recurrences would occur frequently
before an upcoming feverish illness is recognized.
This is a problem inherent to any intermittent pre-
ventive treatment of febrile seizure recurrences, be-
cause it reduces the preventive efficacy. We found a
recurrent febrile seizure the presenting sign of fever
in 22 (33%) of all 67 recurrences (Table 2). Likewise,
in a study comparing intermittent diazepam admin-
istered rectally during fever and no preventive treat-
ment, the fever was not recognized previously in 7
(33%) of the 21 recurrences in the intermittent diaz-
epam group.28 In another study of oral intermittent
diazepam versus placebo, the seizure was the first
manifestation of fever in 42% (14/33) of all seizure
recurrences.29 In a study comparing diazepam with
valproic acid, both administered rectally during fe-
ver only, there were no signals of an upcoming fe-
verish illness in 31% (11/36) of all seizure recurrenc-
es.30 In a study comparing oral diazepam with
placebo during fever, 60% (68/113) of febrile seizure
recurrences occurred without the child receiving the
study medication, in part because the seizure was the
first sign of illness.31
Until recently, children with recurrent febrile sei-
zures were treated with continuous antiepileptic
drugs to prevent further recurrences. Because of the
severe negative side effects and the debatable effi-
cacy, continuous antiepileptic treatment of children
TABLE 4. Previous Randomized Controlled Studies of Prevention of Febrile Seizure Recurrences, Including Antipyretic Treatment
Camfield, 1980 Schnaiderman, 1993 Uhari, 1995
Treatment groups (number of
children)
Single daily dose of
phenobarbital per os 5
mg/kg plus antipyretic
instruction of the parents
(n 5 39) versus antipyretic
instruction including oral
antipyretics only (n 5 40)
Prophylaxis of acetaminophen
orally 15–20 mg/kg per 4-
hourly dose (n 5 53) versus
sporadic usage of
acetaminophen of a similar
oral dose contingent at fever
.37.9°C (n 5 51)
Diazepam 0.2 mg/kg 8-hourly
during fever .38.5°C (n 5
81), of which the first dose to
be given rectally and
additional doses per os,
versus placebo (n 5 80);
additional: cross-over per
fever episode with
acetaminophen 10 mg/kg 6-
hourly during fever .40.0°C
(route of administration not
reported) versus placebo
Temperature measurements Oral and rectal measurements
by the parents at home
Rectal measurements by nurses
or parents during
hospitalization
Measurements by the parents at
home (oral or rectal)
Outcome measure First febrile seizure recurrence
in the same or following
fever episodes
First febrile seizure recurrence
in the same fever episode
(multiple type)
Number of febrile seizure
recurrences in any of the
following fever episodes
Body temperature Body temperature
Maximum study duration 12 mo One fever episode 2 y
Patient inclusion Simple initial febrile seizure Simple initial febrile seizure Simple or complex initial febrile
seizure
Major difficulties in the
evaluation of the results
No standardization of the
antipyretic treatmenta
No placebo control group of
antipyretic treatment
No standardization of the
antipyretic treatmentb
No placebo control group of
antipyretic treatment
Noncomparable outcome
measure
Results 2 of the 39 patients using
phenobarbital plus antipyretic
instruction and 10 of the 40
patients with only instruction
had a recurrent febrile
seizurec
4 of the 53 children using
ongoing prophylaxis vs 5 of
the 51 children in the
sporadic-use group had a
recurrent seizure in the same
fever episode
9 of the 173 fever episodes were
associated with a recurrence
in the acetaminophen group
vs 14 of the 170 fever
episodes in the placebo
groupd
Efficacy of antipyretic
preventive treatment
as concluded
Not effective Not effective Not effective
a All parents received instructions about fever control; no standardized dose per kilogram of bodyweight was administered.
b All parents were allowed to administer extra antipyretics whenever they believed they should.
c Survival analysis was performed to compare seizure recurrence in the phenobarbital-plus-instruction group and the instruction-only
group (P , .02, log-rank).
d Survival analysis was performed to compare seizure recurrence in the diazepam group and the placebo group (P 5 .41, log-rank).
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with febrile seizures nowadays is considered obso-
lete in general, unless there are strong indications for
its use.14 Accordingly, intermittent preventive treat-
ment with diazepam during fever is associated with
adverse effects and has not been proven effective in
a meta-analysis14; only children with a high risk of
febrile seizure recurrence may benefit from intermit-
tent diazepam in an oral dose of 0.33 mg/kg admin-
istered every 8 hours during fever.31 The decision to
prescribe it should be made in consultation with the
parents because of its negative side effects, the ne-
cessity of regular medical check ups, and the diffi-
culty of early recognition of a feverish illness. Neg-
ative consequences of focusing on prevention of
seizure recurrence may entail an iatrogenous fear of
the parents unwittingly encouraged by the pediatri-
cian.32 Probably the most important issue in treating
children with febrile seizures is to make efforts to
reduce parental anxiety by providing information
about the excellent prognosis for children with fe-
brile seizures.9–11,33
We conclude that there is no evidence supporting
intermittent antipyretic treatment to prevent febrile
seizure recurrences. Antipyretics may be given dur-
ing a febrile illness,with the aim to make the child
feel more comfortable. Consultation with the parents
should emphasize the generally benign character of
febrile seizures.
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